Advertisement Corixa and Lorantis to develop hepatitis B vaccine - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Corixa and Lorantis to develop hepatitis B vaccine

Corixa Corporation and Lorantis have formed a joint collaboration to continue the development of a therapeutic hepatitis B vaccine, containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, that was previously owned by Apovia.

This collaboration builds on the initial R&D conducted by Corixa and Apovia for the development of a therapeutic vaccine for the treatment of hepatitis B. Lorantis has acquired all of Apovia’s interest in the hepatitis B vaccine technology and under the terms of the new agreement, Lorantis will assume many of Apovia’s development responsibilities.

The collaboration is managed by a joint management team, with Corixa taking the lead for the regulatory applications and management of all clinical trials. Lorantis will lead the completion of preclinical studies and supply the hepatitis B core antigen. The companies will share equally in all costs and potential revenues associated with the development of the vaccine.

Following proof-of-principle clinical trials, the companies intend to partner the vaccine to a late-stage development and commercialization organization.

“This partnership with Corixa should ensure that CV-1831 will be competitively developed,” said Stefan Fischer, CEO of Lorantis. “Our investment in this therapeutic hepatitis B vaccine is the first step to transform Lorantis from a research driven company into a development focused company as we build our immunology portfolio.”